Intro

This chapter delves into key findings from the ESMO 2024 conference, particularly the Niagara trial exploring dervalumab's effectiveness with chemotherapy for muscle-invasive bladder cancer. Additionally, it discusses future trials and the impact of ctDNA assessment on treatment protocols.